Fluticasone furoate/vilanterol

🧮 Dose calculator

Chronic obstructive pulmonary disease (COPD) · Regimen source: FDA Breo Ellipta · 2.1

• • Rinse mouth after use (candidiasis). Not more than once every 24 h. Use a SABA for breathlessness between doses. FDA Breo Ellipta · 2.3FDA Breo Ellipta · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Breo Ellipta · 8.1

  “Risk Summary There are insufficient data on the use of BREO ELLIPTA or its individual components, fluticasone furoate and vilanterol, in pregnant women to inform a drug-associated risk.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Breo Ellipta · 8.2

  “Risk Summary There is no information available on the presence of fluticasone furoate or vilanterol in human milk, the effects on the breastfed child, or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Breo Ellipta · 8.4

  “The safety and effectiveness of BREO ELLIPTA for the maintenance treatment of asthma in pediatric patients 5 years of age and older have been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Breo Ellipta · 8.5

  “No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.